Patents by Inventor John Mark Ellard

John Mark Ellard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of plasma kallikrein and uses thereof
    Patent number: 12441724
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: April 20, 2022
    Date of Patent: October 14, 2025
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Nikolaos Papaioannou, Sarah Jocelyn Fink, Thomas Allen Miller, Gerald Wayne Shipps, Jr., Jeremy Mark Travins, David Edward Ehmann, Alastair Rae, John Mark Ellard
  • Plasma kallikrein inhibitors and uses thereof
    Patent number: 12221441
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: August 16, 2023
    Date of Patent: February 11, 2025
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Nikolaos Papaioannou, Jeremy Mark Travins, Sarah Jocelyn Fink, John Mark Ellard, Alastair Rae
  • PLASMA KALLIKREIN INHIBITORS
    Publication number: 20240382482
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: March 16, 2022
    Publication date: November 21, 2024
    Inventors: Nikolaos PAPAIOANNOU, Jeremy Mark TRAVINS, Sarah Jocelyn FINK, John Mark ELLARD, Alastair RAE, Jonathan Andrew SPENCER
  • Heteroaryl plasma kallikrein inhibitors
    Patent number: 12065448
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: June 3, 2022
    Date of Patent: August 20, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Nikolaos Papaioannou, Jeremy Mark Travins, Sarah Jocelyn Fink, John Mark Ellard, Alastair Rae
  • INHIBITORS OF PLASMA KALLIKREIN
    Publication number: 20240226106
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: March 16, 2022
    Publication date: July 11, 2024
    Inventors: Nikolaos PAPAIOANNOU, Jeremy Mark TRAVINS, Sarah Jocelyn FINK, John Mark ELLARD, Alastair RAE
  • HETEROARYL INHIBITORS OF PLASMA KALLIKREIN
    Publication number: 20240228488
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: March 16, 2022
    Publication date: July 11, 2024
    Inventors: Nikolaos PAPAIOANNOU, Jeremy Mark TRAVINS, Sarah Jocelyn FINK, John Mark ELLARD, Alastair RAE, Jonathan Andrew SPENCER, Stuart Shane RANKIN, Robert Staurt Laurie CHAPMAN
  • IMIDAZOPYRIDINYL INHIBITORS OF PLASMA KALLIKREIN
    Publication number: 20240199612
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: March 16, 2022
    Publication date: June 20, 2024
    Inventors: Nikolaos PAPAIOANNOU, Jeremy Mark TRAVINS, Sarah Jocelyn FINK, John Mark ELLARD, Alastair RAE
  • POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN
    Publication number: 20240199613
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: March 16, 2022
    Publication date: June 20, 2024
    Inventors: Nikolaos PAPAIOANNOU, Jeremy Mark TRAVINS, Sarah Jocelyn FINK, John Mark ELLARD, Alastair RAE, Stuart Shane RANKIN, Robert Staurt Laurie CHAPMAN
  • PLASMA KALLIKREIN INHIBITORS AND USES THEREOF
    Publication number: 20230391773
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: August 16, 2023
    Publication date: December 7, 2023
    Inventors: Nikolaos Papaioannou, Jeremy Mark Travins, Sarah Jocelyn Fink, John Mark Ellard, Alastair Rae
  • Plasma Kallikrein inhibitors and uses thereof
    Patent number: 11787796
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: October 17, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Nikolaos Papaioannou, Jeremy Mark Travins, Sarah Jocelyn Fink, John Mark Ellard, Alastair Rae
  • INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF
    Publication number: 20230078513
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: April 20, 2022
    Publication date: March 16, 2023
    Inventors: Nikolaos Papaioannou, Sarah Jocelyn Fink, Thomas Allen Miller, Gerald Wayne Shipps, JR., Jeremy Mark Travins, David Edward Ehmann, Alastair Rae, John Mark Ellard
  • HETEROARYL PLASMA KALLIKREIN INHIBITORS
    Publication number: 20220298176
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: June 3, 2022
    Publication date: September 22, 2022
    Inventors: Nikolaos Papaioannou, Jeremy Mark Travins, Sarah Jocelyn Fink, John Mark Ellard, Alastair Rae
  • Heteroaryl plasma kallikrein inhibitors
    Patent number: 11370803
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: June 28, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Nikolaos Papaioannou, Jeremy Mark Travins, Sarah Jocelyn Fink, John Mark Ellard, Alastair Rae
  • Inhibitors of plasma kallikrein and uses thereof
    Patent number: 11352356
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: June 7, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Nikolaos Papaioannou, Sarah Jocelyn Fink, Thomas Allen Miller, Gerald Wayne Shipps, Jr., Jeremy Mark Travins, David Edward Ehmann, Alastair Rae, John Mark Ellard
  • PLASMA KALLIKREIN INHIBITORS AND USES THEREOF
    Publication number: 20210078999
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: September 17, 2020
    Publication date: March 18, 2021
    Inventors: Nikolaos Papaioannou, Jeremy Mark Travins, Sarah Jocelyn Fink, John Mark Ellard, Alastair Rae
  • HETEROARYL PLASMA KALLIKREIN INHIBITORS
    Publication number: 20210079022
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: September 17, 2020
    Publication date: March 18, 2021
    Inventors: Nikolaos Papaioannou, Jeremy Mark Travins, Sarah Jocelyn Fink, John Mark Ellard, Alastair Rae
  • INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF
    Publication number: 20200317667
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: June 22, 2020
    Publication date: October 8, 2020
    Inventors: Nikolaos Papaioannou, Sarah Jocelyn Fink, Thomas Allen Miller, Gerald Wayne Shipps, JR., Jeremy Mark Travins, David Edward Ehmann, Alastair Rae, John Mark Ellard
  • Inhibitors of plasma kallikrein and uses thereof
    Patent number: 10730874
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: August 4, 2020
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Nikolaos Papaioannou, Sarah Jocelyn Fink, Thomas Allen Miller, Gerald Wayne Shipps, Jr., Jeremy Mark Travins, David Edward Ehmann, Alastair Rae, John Mark Ellard
  • INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF
    Publication number: 20190284182
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: March 12, 2019
    Publication date: September 19, 2019
    Inventors: Nikolaos Papaioannou, Sarah Jocelyn Fink, Thomas Allen Miller, Gerald Wayne Shipps, JR., Jeremy Mark Travins, David Edward Ehmann, Alastair Rae, John Mark Ellard
  • Oxazole tyrosine kinase inhibitors
    Patent number: 9187465
    Abstract: The invention provides a compound which is an amide of the formula (1), or a salt, solvate, N-oxide or tautomer thereof; wherein: a is 0 or 1; b is 0 or 1: provided that the sum of a and b is 0 or 1; T is O or NH Ar1 is a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group containing up to 4 heteroatoms selected from O, N and S, and being optionally substituted by one or more substituents R1; Ar2 Js a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group containing up to 4 heteroatoms selected from O, N and S and being optionally substituted by one or more substituents R2; and R1 and R2 are as defined in the claims. The compounds are inhibitors of kinases and in particular FLT3, FLT4 and Aurora kinases.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: November 17, 2015
    Assignee: SAREUM LIMITED
    Inventors: John Charles Reader, John Mark Ellard, Helen Boffey, Susanne Taylor, Andrew David Carr, Michael Cherry, Michelle Wilson, Richard Boakye Owoare